Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia

被引:26
作者
Hsueh, Po-Ren
Hawkey, Peter Michael
机构
[1] Natl Taiwan Univ Hosp, Coll Med, Dept Lab Med, Div Clin Microbiol, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Coll Med, Dept Internal Med, Div Infect Dis, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Coll Med, Dept Internal Med, Div Clin Microbiol, Taipei, Taiwan
[4] Univ Birmingham, Sch Med, Birmingham, W Midlands, England
[5] Birmingham Heartlands & Solihull NHS Trusts, Hlth Protect Agcy, W Midlands Publ Hlth Lab, Birmingham, W Midlands, England
关键词
intra-abdominal infections; antimicrobial therapy; Asia; consensus; SUSCEPTIBILITIES; RESISTANCE; AGENTS;
D O I
10.1016/j.ijantimicag.2007.03.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The selection of antimicrobial agents in the 2006 Guidelines (consensus statement) on Empiric Therapy for Complicated Intra-Abdominal Infections (IAIs) in Asia was based on resistance and epidemiological data from the Asian region. In these 2006 guidelines, single agent therapy using the beta-lactam/beta-lactamase inhibitors ampicillin/sulbactam or cefoperazone-sulbactam is recommended for mild-to-moderate cases, while piperacillin-tazobactam is recommended for high-severity cases. When using carbapenems, ertapenem is recommended for mild-to-moderate cases, while imipenem and meropenem are recommended for high-severity cases. For combination regimes, two types of agents are recommended: cephalosporin-based and monobactam-based. For mild-to-moderate cases, a third generation cephalosporin plus metronidazole is recommended. For high-severity cases, a third or fourth generation cephalosporin plus metronidazole +/- amikacin is recommended. For the monobactam-based regimen, aztreonam plus metronidazole is recommended for high-severity cases only. (c) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:129 / 133
页数:5
相关论文
共 7 条
[1]   In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends) [J].
Hsueh, Po-Ren ;
Snyder, Theresa A. ;
DiNubile, Mark J. ;
Satischandran, Vilas ;
McCarroll, Kathleen ;
Chow, Joseph W. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 28 (03) :238-243
[2]  
Lee S.F., 1996, FOOD SCI, V23, P1
[3]  
Lin Wei-Jen, 2006, Journal of Microbiology Immunology and Infection, V39, P249
[4]  
Mazuski John E, 2002, Surg Infect (Larchmt), V3, P161, DOI 10.1089/109629602761624171
[5]  
Shinagawa Nagao, 2006, Japanese Journal of Antibiotics, V59, P72
[6]   Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections [J].
Solomkin, JS ;
Mazuski, JE ;
Baron, EJ ;
Sawyer, RG ;
Nathens, AB ;
DiPiro, JT ;
Buchman, T ;
Dellinger, EP ;
Jernigan, J ;
Gorbach, S ;
Chow, AW ;
Bartlett, J .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (08) :997-1005
[7]   High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan [J].
Teng, LJ ;
Hsueh, PR ;
Tsai, JC ;
Liaw, SJ ;
Ho, SW ;
Luh, KT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (09) :2908-2913